Eczema Herpeticum: When Herpes Complicates Eczema

Clinical Overview

Eczema herpeticum is a severe, disseminated herpes simplex virus (HSV) infection that occurs in patients with atopic dermatitis or other compromised skin barrier conditions. The condition represents a medical emergency requiring prompt recognition and aggressive systemic antiviral therapy. Unlike primary HSV infection, which typically manifests with localized clustered vesicles and systemic symptoms, eczema herpeticum presents with widespread vesicular eruption often occurring simultaneously across multiple body sites affected by underlying eczema. The condition results from impaired local immune defenses in eczematous skin, allowing HSV to disseminate beyond the initial site of viral inoculation. Eczema herpeticum predominantly affects patients with atopic dermatitis, though it can occur in other conditions with compromised skin barrier (severe seborrheic dermatitis, psoriasis, or other inflammatory dermatoses). The condition carries significant morbidity and potential mortality if untreated; complications including severe secondary bacterial infection, systemic viral dissemination, and encephalitis can occur. Early recognition and treatment are critical for optimal outcomes.

Epidemiology

Eczema herpeticum occurs in approximately 2-3% of patients with atopic dermatitis during their lifetime, with some population-based studies estimating higher frequencies (up to 5-10% in severe atopic dermatitis). Peak incidence occurs in infants and young children (typically <2 years of age), though eczema herpeticum can occur at any age in atopic individuals. The condition shows no significant gender predominance. Primary occurrence (first HSV infection in an atopic patient) typically occurs in young children with severe atopic dermatitis, while recurrent eczema herpeticum (reactivation of latent HSV) can occur at any age in atopic individuals with prior HSV exposure. Risk factors significantly increasing incidence include: severe atopic dermatitis with extensive active inflammation and barrier disruption, young age (particularly infants and toddlers with immature immune responses), primary HSV infection (highest risk), and intense HSV exposure (occupational exposure in healthcare workers or personal contact with HSV-infected individual). Seasonal variation may occur, correlating with seasonal exacerbations of atopic dermatitis in some patients. Geographic variation is minimal; eczema herpeticum is recognized worldwide with incidence correlating with prevalence of both atopic dermatitis and HSV exposure in given population.

Pathophysiology

The pathophysiology of eczema herpeticum involves interaction of multiple factors: impaired skin barrier function from underlying atopic dermatitis, reduced local antiviral immune responses in eczematous skin, and virulent HSV strains. Atopic dermatitis results in profound barrier dysfunction with reduced filaggrin expression, altered lipid composition, and impaired production of antimicrobial peptides including cathelicidins and defensins. These antimicrobial peptides normally provide first-line defense against viral infection; their reduction in atopic skin allows enhanced viral replication. Th2 cytokine skewing characteristic of atopic dermatitis (elevated IL-4, IL-5, IL-13) impairs Th1 antiviral responses necessary for HSV control. Reduced production of interferon-gamma (IFN-γ) and other Th1 cytokines compromises antiviral immunity. When HSV contacts compromised eczematous skin (through direct contact with HSV-infected individual or autoinoculation), the virus initiates replication with minimal opposition from impaired local immune responses. In normal individuals, HSV causes localized infection with robust local immune response including keratinocyte interferon production, rapid infiltration of natural killer cells and CD8+ T lymphocytes, and containment of infection. In atopic individuals, these responses are blunted; HSV replicates extensively and disseminates to adjacent skin areas affected by atopic dermatitis through direct viral spread (cell-to-cell transmission) rather than hematogenous dissemination. The simultaneous appearance of vesicles across multiple eczematous body areas (characteristic of eczema herpeticum) results from this contiguous spread through compromised barrier areas rather than systemic viremia. Histologically, affected skin demonstrates characteristic features of HSV infection including ballooning degeneration of keratinocytes, intranuclear inclusions, and multinucleated giant cells, superimposed on background atopic dermatitis inflammation.

Clinical Presentation

Eczema herpeticum typically presents acutely with sudden onset of grouped vesicles developing simultaneously across multiple body areas affected by atopic dermatitis, often accompanied by systemic symptoms including fever, malaise, and regional lymphadenopathy. The lesions are typically 1-3 mm diameter vesicles arranged in clusters, often on erythematous base. The distribution follows the pattern of underlying atopic dermatitis: commonly affecting face, neck, arms, and torso—wherever eczematous skin is present. Unlike primary HSV with lesions confined to specific sites (lips, genitals, buttocks), eczema herpeticum shows widespread distribution reflecting dissemination across all areas of compromised skin. The vesicles rapidly progress to pustules and crusted lesions over 7-10 days. Pruritus is typically intense. Associated systemic symptoms are common: fever (often 38-39°C), malaise, fatigue, headache, and sometimes gastrointestinal symptoms. Regional lymphadenopathy (cervical, axillary, inguinal) is frequently present. Significant secondary bacterial infection occurs in 25-50% of cases, manifesting as increased purulence, cellulitis, and potential systemic signs of infection including sepsis if untreated. Some patients develop complications including severe secondary bacterial infection with potential for sepsis, herpes keratitis (HSV infection of cornea causing ocular pain and potential vision impairment), or in rare cases, disseminated herpes with visceral involvement or HSV encephalitis. The course without treatment is one of progressive dissemination over 7-10 days with eventual spontaneous resolution due to development of adequate immune response (typically 2-4 weeks if untreated). However, mortality approaches 3% in untreated severe eczema herpeticum, particularly in infants.

Diagnosis

Diagnosis of eczema herpeticum requires high clinical suspicion based on presentation of acute vesicular eruption with simultaneous involvement of multiple eczematous body areas in a patient with known atopic dermatitis or other compromised skin condition. Key diagnostic features include: (1) acute onset of grouped vesicles on erythematous base; (2) widespread distribution across multiple body areas; (3) simultaneous appearance of lesions; (4) associated systemic symptoms including fever; (5) in context of underlying atopic dermatitis. Direct viral identification confirms diagnosis: Tzanck preparation (Wright or Giemsa stain of vesicular fluid) demonstrates multinucleated giant cells and acantholytic cells consistent with HSV; sensitivity is moderate (60-80%) but allows rapid presumptive diagnosis. Viral culture on specimen from vesicular fluid is gold standard but takes 3-7 days for results; culture identifies HSV type (I or II) and allows antiviral susceptibility testing. Polymerase chain reaction (PCR) of vesicular fluid or crusted lesion is most sensitive and allows rapid (24-48 hour) identification of HSV. Herpes simplex serology (HSV IgM and IgG) is helpful in distinguishing primary infection (IgM positive, IgG negative) from recurrent infection (both positive or IgG positive only), though serology should not delay treatment initiation. Skin biopsy is rarely necessary but demonstrates characteristic HSV cytopathic changes including ballooning degeneration, acantholysis, and intranuclear inclusions. Bacterial culture of lesions should be obtained if secondary bacterial infection is suspected. Complete blood count may show lymphocytosis. Testing for systemic dissemination (blood cultures if sepsis suspected, ophthalmologic examination if ocular involvement suspected, lumbar puncture with cerebrospinal fluid (CSF) HSV PCR if encephalitis suspected) should be performed if clinical suspicion for complications is high. Differential diagnosis includes: bacterial folliculitis or impetigo (distinguished by absence of characteristic vesiculation and faster clinical course), varicella (distinguished by more generalized distribution, different morphology, and varicella-zoster virus PCR or serology), and other viral exanthems.

Treatment Algorithm

Eczema herpeticum requires urgent systemic antiviral therapy initiated immediately upon clinical suspicion; treatment should not be delayed awaiting confirmatory testing results. Acyclovir remains the standard treatment and should be initiated immediately.

Systemic acyclovir intravenously is recommended for moderate-to-severe eczema herpeticum: acyclovir 10-15 mg/kg IV every 8 hours for 7-10 days. This dose ensures adequate CSF penetration and systemic viral suppression. Intravenous administration is preferred for initial treatment of eczema herpeticum due to need for rapid high serum levels. For milder cases or after initial IV therapy, oral acyclovir 400-800 mg five times daily for 7-10 days is appropriate. Valacyclovir (2-3 g three times daily) or famciclovir (500 mg three times daily) are more convenient oral alternatives with superior bioavailability compared to acyclovir. Antiviral therapy duration should be 7-10 days; prolonged therapy (>10 days) is not generally recommended unless complications are present.

Supportive care is critical. Gentle cleansing of lesions with normal saline 2-3 times daily helps remove debris and reduces risk of secondary bacterial infection. Cool compresses applied for 10-15 minutes multiple times daily provide symptomatic relief. Emollients should be applied to non-lesional skin to support barrier repair, though care should be taken to avoid occlusion of lesions. Patients should avoid scratching despite intense pruritus; short fingernails and consideration of protective gloves may help prevent autoinoculation and secondary bacterial infection.

Pruritus management with systemical antihistamines including hydroxyzine 25-50 mg at bedtime may reduce scratching and improve sleep quality. Topical antipruritics should be avoided on active lesions due to risk of irritation.

Secondary bacterial infections require prompt management. Culture-guided antibiotic therapy is strongly recommended given the high incidence of resistant organisms in this population. Empiric treatment with broad-spectrum coverage including MRSA coverage is reasonable: oral clindamycin 300-450 mg three or four times daily, or trimethoprim-sulfamethoxazole (TMP-SMX) double-strength twice daily for 10-14 days. For more severe infections with systemic toxicity, intravenous antibiotics (nafcillin 1-2 g every 4-6 hours or vancomycin 15-20 mg/kg every 8-12 hours) are appropriate. Topical antibiotics (mupirocin ointment) should not be used alone as systemic therapy is necessary; topical agents may be used adjunctively to prevent secondary infection of specific lesions.

Optimization of underlying atopic dermatitis therapy accelerates recovery. Topical corticosteroids may be continued on non-lesional eczematous skin; however, areas with active HSV lesions should not receive topical corticosteroids. Emollients should be liberally applied. Systemic corticosteroids should be avoided as they may worsen HSV infection severity.

Ocular examination should be performed to assess for HSV keratitis, particularly if facial involvement is present or if ocular symptoms (pain, photophobia, foreign body sensation) develop. If keratitis is identified, consultation with ophthalmology is necessary; treatment may include topical antivirals (trifluridine drops) in addition to systemic therapy.

Prognosis

The prognosis of eczema herpeticum is generally favorable with prompt initiation of systemic antiviral therapy. Approximately 95% of patients achieve complete resolution of lesions within 2-4 weeks with appropriate antiviral treatment. Factors influencing prognosis include: timeliness of antiviral therapy initiation (early treatment substantially improves outcomes), severity of underlying atopic dermatitis, patient age (infants show higher morbidity and mortality), and presence of complications including secondary bacterial infection or systemic dissemination. Complications are uncommon with appropriate treatment but carry significant morbidity: herpes keratitis may result in scarring and vision impairment, disseminated herpes with visceral involvement carries mortality risk, and HSV encephalitis has mortality of 10-20% even with treatment. Recurrent eczema herpeticum occurs in 20-30% of patients with severe atopic dermatitis; recurrences are typically less severe than primary infection due to development of HSV-specific immunity. Long-term prognosis is substantially improved by optimization of atopic dermatitis control; patients with well-controlled atopic dermatitis show reduced risk of recurrent eczema herpeticum. Post-exposure prophylaxis with oral acyclovir or valacyclovir may be considered for severely atopic individuals with known exposure to HSV.

When to See a Dermatologist

Urgent dermatologic (or general medical) evaluation is mandatory for suspected eczema herpeticum. This represents a medical emergency requiring immediate hospitalization and systemic antiviral therapy. Patients should be evaluated in emergency department or acute care setting if eczema herpeticum is suspected. Ongoing specialist care is appropriate for: (1) confirmation of diagnosis; (2) assessment for complications (keratitis, systemic dissemination); (3) optimization of underlying atopic dermatitis therapy to prevent recurrence; (4) management of significant secondary bacterial infection; (5) counseling regarding prevention of future episodes.

Frequently Asked Questions

Q: Is eczema herpeticum contagious? A: Yes, eczema herpeticum is highly contagious. Patients with active lesions shed infectious HSV and can transmit the virus to others through direct contact. Patients should practice strict hand hygiene, avoid touching others, and ideally maintain isolation from vulnerable individuals (immunocompromised, severe atopic dermatitis) during active disease.

Q: Can eczema herpeticum be prevented? A: Prevention includes: strict avoidance of contact with individuals with active HSV infection, prompt treatment of any skin breaks or infections that might serve as entry points for HSV, and optimization of atopic dermatitis control to maintain barrier function. For severely atopic individuals with known exposure to HSV, post-exposure prophylaxis with oral acyclovir or valacyclovir may be considered.

Q: Is eczema herpeticum life-threatening? A: Eczema herpeticum can be severe and potentially life-threatening if untreated, particularly in infants or immunocompromised individuals. However, with prompt initiation of systemic antiviral therapy, mortality is rare (<1-2% with treatment). Early recognition and treatment are critical.

Q: Can I get eczema herpeticum more than once? A: Yes, recurrent eczema herpeticum occurs in 20-30% of patients with severe atopic dermatitis. However, recurrences are typically less severe than primary infection due to development of HSV-specific immunity from prior infection.

References